Axonics® Announces U.S. Food & Drug Administration Approves Use of Full-Body MRI for Pivotal Study Patients
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable sacral neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced the U.S. Food & Drug Administration (“FDA”) approved the use of full-body magnetic resonance imaging (“MRI”) using 1.5 Tesla MRI scanners for clinical study patients implanted with the Axonics System.
The approval was a result of a supplement filed by Axonics with the FDA under the Investigational Device Exemption (“IDE”) regarding the Company’s ARTISAN-SNM 129-patient pivotal clinical study. The FDA concluded that Axonics provided sufficient data to support full-body MRIs.
Raymond W. Cohen, CEO of Axonics, commented, “Allowing full-body MRI scans for our clinical study patients means that none will have to undergo an explant of their neurostimulator device should they require an MRI. We view this as a very positive step by the FDA that underscores the quality of data that Axonics has submitted to the agency. Given this approval, we are confident that this capability will be included as part of the Axonics SNM System premarket approval (“PMA”) approval, which is anticipated in the second half of 2019.”
The Axonics System1 is the first rechargeable SNM system approved for sale in Europe, Canada and Australia and is currently under PMA review by the FDA. Axonics offers a long-lived miniaturized neurostimulator that is approximately the size of a USB stick and is qualified to last at least 15 years in the body, as compared to the only competitive device on the market from Medtronic, which requires replacement every 3 to 5 years. The Axonics System also features many other differentiating attributes, including a patented tined lead, a wireless charging system optimized for infrequent charging, a key fob size easy-to-use patient remote control and an intuitive clinician programmer that facilitates lead placement and stimulation programming.
About Overactive Bladder and Sacral Neuromodulation
Overactive bladder (OAB) includes urinary urge incontinence and urinary frequency and affects an estimated 85 million adults in the U.S. and Europe. OAB is caused by a miscommunication between the bladder and the brain and significantly impacts quality of life. SNM therapy is a well-established treatment that has been widely employed to reduce symptoms and restore bladder function and is also employed to treat urinary retention and fecal incontinence. Reimbursement for SNM is well established in the United States and is a covered service in Europe, Canada and Australia.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics System is the first rechargeable sacral neuromodulation system approved for sale in Europe, Canada and Australia and the first SNM system to gain full-body MRI conditional labeling in Europe. For more information, visit the Company’s website at www.axonicsmodulation.com
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.
1 The Axonics r-SNM System is currently under PMA review and is designated as an investigational medical device
Axonics Modulation Technologies, Inc.
Dan Dearen, +1-949-396-6320
President & Chief Financial Officer
Investor & Media Contact
Zack Kubow + 1-415-658-6436
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Norwegian Video Trailblazers Create Neat to Change the Game with Zoom15.10.2019 16:00:00 CEST | Press release
Today at Zoomtopia 2019, Neat, a trailblazing Norwegian startup, launched its portfolio of meeting room systems designed for Zoom Video Communications, Inc. (NASDAQ: ZM). Neat's video devices are built from the ground up and developed in close partnership with Zoom. The systems are as easy to buy and set up as any consumer product, while providing complete enterprise-grade management and security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005773/en/ Zoom Video Systems by Neat (Photo: Business Wire) Neat's systems embrace breakthrough technology to eliminate the complexities of video in meeting rooms, along with simplifying the entire user experience. The company has reimagined every aspect of the Zoom Rooms customer journey, including how people buy, install, use and manage its products. Based in Oslo, Norway (aka "Video Valley”), Neat has offices in the US, UK, and Taiwan. Although the company is new, Neat’s team
The success story of the Aloe Vera Drinking Gel by LR Health & Beauty continues15.10.2019 15:23:00 CEST | Press release
LR Health & Beauty is further expanding its Aloe vera product portfolio with its new product Aloe Vera Drinking Gel Immune Plus. The development and manufacturing of Aloe vera products has been one of the core competences of the global direct sales company for more than 17 years. True to the motto "More quality for your life", LR now presents Immune Plus as a premium product to support the immune system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005834/en/ The success story of the Aloe Vera Drinking Gel by LR Health & Beauty continues (Photo: Business Wire) The Aloe Vera Drinking Gels have been LR’s bestsellers since 2002. They offer support in different life situations and are available in various flavors. The special feature of Immune Plus is the synergetic interaction of the ingredients – 85% Aloe vera leaf gel with 8% honey, 6% ginger juice and lemon juice, enriched with vitamin C, zinc and selenium – which ha
International Experts Invited to Attend Riyadh’s Sustainable City Symposium15.10.2019 14:49:00 CEST | Press release
The Royal Commission for Riyadh City (RCRC), formally known as Riyadh Development Authority, has invited international experts to participate in a Symposium setting out the next chapter in Riyadh’s development as a sustainable city, one that will enhance the lives of its citizens, while finding solutions to the difficult challenges facing all cities across the world today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005797/en/ International Experts Invited to Attend Riyadh’s Sustainable City Symposium (Photo: AETOSWire) ‘Riyadh’s Sustainable Future’ Symposium will take place on November 12 & 13, 2019 in Riyadh and will focus on four of the capital’s most ambitious projects, launched by King Salman bin Abdulaziz Al Saud, and stemming from an initiative from Prince Mohammed bin Salman bin Abdulaziz Al Saud, the Crown Prince. These four projects are transformative and will help to establish Riyadh as one of the most li
Mundipharma presents wealth of data for Penthrox®▼ (methoxyflurane) at EUSEM Congress, demonstrating superiority compared to standard of care in trauma pain in adults15.10.2019 14:05:00 CEST | Press release
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY Mundipharma presents new data for the inhaled analgesic Penthrox ® (methoxyflurane)6 at the European Society for Emergency Medicine (EUSEM) Congress 2019, from 12–16 October. Five abstracts are being presented, advancing the understanding of the use of methoxyflurane in the treatment of moderate to severe trauma-related pain for adults in emergency settings in Europe: MEDITA Study1 #18647: the first study to directly compare the effectiveness of methoxyflurane to standard analgesic treatment (SAT) – IV morphine for severe pain, and IV paracetamol or ketoprofen for moderate trauma pain in Italy. Methoxyflurane was superior to IV morphine (severe pain) and IV paracetamol or IV ketoprofen (moderate pain) for the primary endpoint, defined as the change in pain intensity over the first 10 minutes (overall adjusted mean treatment difference: 5.94mm; 95% CI: 8.83, 3.06mm) following pain treatment administration.1 Methoxyflurane was rated as ‘excellent
British Firm BitePRO Claim Education Professionals Are Bitten By Pupils On Daily Basis15.10.2019 14:00:00 CEST | Press release
According to British firm BitePRO, teachers and education professionals are at increased risk of being bitten by pupils and the consequences can be severe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015005707/en/ Kayleigh Davis, BitePRO's Senior Consultant on the protection from human bites. (Photo: Business Wire) Human bites can more dangerous than animal bites because of the large quantity and types of bacteria and viruses contained in the human mouth. Human bites that break the skin can become severely infected. According to several medical sources, human bites have been shown to transmit hepatitis B, hepatitis C, herpes simplex virus (HSV) syphilis, tuberculosis, actinomycosis, tetanus and even the human immunodeficiency virus (HIV). Robert Kaiser, CEO of BitePRO a firm specialised in bite resistant clothing states: “We are fully aware of teachers working in special educational needs schools or units for pupils wi
Andersen Global Enters Cameroon, Marking 18th Country in Africa15.10.2019 13:30:00 CEST | Press release
Andersen Global is excited to announce it has signed a collaboration agreement with Muluh & Partners, a law firm based in Douala, Cameroon. In a period of just over two years, Andersen Global has now expanded its presence into 18 countries in Africa. Founded in 2012, Muluh & Partners is a full-service law firm with five partners. The firm’s professionals provide legal and tax advice to clients in the areas of mining, aviation, banking and finance, alternate dispute resolution, cybercrimes, immigration, energy, forest exploration, transnational crime, agribusiness, due diligence, international trade, intellectual property, maritime, business/corporate, contracts and telecommunication technology law. “Our philosophy is simple: offer best-in-class service, treat clients like family, and provide them with transparency throughout the process,” said Jude Muluh, Office Managing Director for Muluh & Partners. “Collaborating with Andersen Global will only strengthen the quality of services that